After a slow start, the drug has emerged as the star of AbbVie's ... Vraylar exerted its benefit at a lower dose (1.5 mg/day) but not at a Higher dose (3.0 mg/kg), undermining the top-line finding.

FDA approves Symbravo for acute migraine relief, combining rizatriptan and meloxicam. Discover its unique benefits and fast absorption for effective symptom control.

The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday. The ...

Most of the tablets included in this guide are older-generation models, so you may have to visit third-party retailers to pick them up, but where possible, we've provided links to those retailers ...

Here’s how it works. Today's Android tablets are multitasking and gaming beasts, with stunning visuals and more customization options than Apple's best. Plus, tablets like the Samsung Galaxy Tab ...

A small tablet can work just as well as (or even better than) larger ones, especially when it comes to lugging one around between classes or in your work bag on your commute. When you're on the ...

We tested the hypothesis that the combination of aripiprazole and clozapine would lead to an improvement in this patient group. Methods: Eleven patients with treatment-resistant schizophrenia ...

Are you in the market for a tablet but reluctant to shell out hundreds of pounds in one go? We've scoured the web for a bargain that won't leave your wallet feeling light and have found one that ...

Recently, second-generation antipsychotics (SGAs), olanzapine plus fluoxetine, quetiapine extended release and aripiprazole have clearly demonstrated efficacy in the treatment of MDD patients ...